HOME >> BIOLOGY >> NEWS
Expanding the genetic code: the worlds first truly unnatural organism

From time immemorial, every living thing has shared the same basic set of building blocks -- 20 amino acids from which all proteins are made. That is, until now: A group of scientists say they have, for the first time, created an organism that can produce a 21st amino acid and incorporate it into proteins completely on its own. The research should help probe some of the central questions of evolutionary theory.

The findings are scheduled to appear in the Jan. 29 print edition of the Journal of the American Chemical Society, a peer-reviewed journal of the world's largest scientific society. The article was initially published Jan. 4 on the journal's Web site.

The project could eventually give concrete answers to questions that have generally been regarded as purely speculative: Is 20 the ideal number of basic building blocks? Would additional amino acids lead to organisms with enhanced function? Why has the genetic code not evolved further?

"Why did life settle on 20 amino acids?" asks Ryan Mehl, Ph.D., previously a researcher at the Scripps Research Institute in La Jolla, Calif., and now on the faculty of Franklin & Marshall College in Lancaster, Pa. "Would more amino acids give you a better organism -- one that could more effectively adapt if placed under selective pressure?"

To address this question, Mehl and a team of scientists led by Peter Schultz, Ph.D., professor of chemistry at Scripps, added a pathway to an E. coli bacterium that allows it to make a new amino acid -- p-aminophenylalanine (pAF) -- from simple carbon sources. Analytical techniques showed that pAF was incorporated into proteins with a fidelity rivaling that of the 20 natural amino acids.

"This allows you to have a totally autonomous organism that you can 'race'in one pot by evolving the new bacterium alongside its ancestors with 20 amino acids," says Christopher Anderson, a researcher at Scripps and another author
'"/>

Contact: Beverly Hassell
b_hassell@acs.org
202-872-4065
American Chemical Society
13-Jan-2003


Page: 1 2 3

Related biology news :

1. Expanding the genetic code--TSRI scientists synthesize 21-amino-acid bacterium
2. Expanding lifes alphabet
3. Researchers determine genetic cause of Timothy syndrome
4. Rare childhood genetic syndrome identified
5. New research shows plants can shuffle and paste gene pieces to generate genetic diversity
6. Scientists decipher genetic code of biothreat pathogen
7. Chemical genetics identifies SARS inhibitors
8. 22nd amino acid synthesized and added to genetic code of e. coli bacteria
9. The impact of genetic variations on the treatment of early rheumatoid arthritis
10. Adaptive changes in the genome may provide insight into the genetics of complex disease
11. New genetic hypothesis for the cause of autism

Post Your Comments:
(Date:5/21/2013)... , May 21, 2013 Royal Philips Electronics ... the world,s first portable ultrasound with Philips, industry leading ... capability. The CX50 xMATRIX with available Live 3D TEE ... at the EuroPCR, official meeting for the ... Since its launch in 2012, Philips CX50 ...
(Date:5/21/2013)... modifications, which alter the way genes function without ... detected in the blood of pregnant women during ... foretell depression in the weeks after giving birth, ... debilitating. , The findings of the small study ... the journal Molecular Psychiatry . , "Postpartum ...
(Date:5/20/2013)... to the antibiotic colistin are also commonly resistant ... according to a study in mBio , ... for Microbiology. Cross-resistance to colistin and host antimicrobials ... against bacterial attack, could mean that patients with ... a crippled immune response. Colistin is a last-line ...
Breaking Biology News(10 mins):Philips CX50 xMATRIX now offers world-class interventional and diagnostic features on single portable system 2Genetic predictors of postpartum depression uncovered by Hopkins researchers 2Genetic predictors of postpartum depression uncovered by Hopkins researchers 3Resistance to last-line antibiotic makes bacteria resistant to immune system 2Resistance to last-line antibiotic makes bacteria resistant to immune system 3
(Date:5/21/2013)... Toronto, Canada (PRWEB) May 21, 2013 ... there is a strong push within the industry ... Development and Manufacturing Organizations and pharma companies often ... time frames. , Microtablets, developed in collaboration with ... how effective outsourcing can bring products to market ...
(Date:5/21/2013)... May 21, 2013 Many have long ... contributor to acne. Recently physicians from Clinical Psychiatry.com ... stress on the skin, and suggested using hypnotherapy ... the chemicals produced from stress that cause acne. , ... negative feelings acne brings about, stress causes changes in ...
(Date:5/21/2013)... Emerson Resources Inc. , a premier pharmaceutical ... Company’s Chief Executive Officer and Chairman of the Board, ... service. As part of Emerson Resources’ planned leadership succession ... as Dr. Signorino’s successor. , Dr. Signorino is ... a significant contribution to the field during his extensive ...
(Date:5/21/2013)... 21, 2013  MacroGenics, Inc. today announced that ... (MGAH22), an Fc-modified chimeric monoclonal antibody (MAb), in ... oncoprotein," will be presented at the 2013 Annual ... during the Developmental Therapeutics - Immunotherapy Oral Abstract ... 4:30 PM.  The presentation will describe the results ...
Breaking Biology Technology:The Development of an Innovative Microtablet Dosage Form, a Success Story: Live Webinar Hosted by Xtalks 2Adult Acne Treatment, Probiotic Action Explains How Hypnotherapy and Probiotics May Cure Various Skin Conditions 2Emerson Resources Announces CEO Retirement and Appointment of Successor 2Emerson Resources Announces CEO Retirement and Appointment of Successor 3MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3
Cached News: